After AstraZeneca’s Alexion acquires all remaining equity in Caelum next week it will 'advance and accelerate' ongoing clinical development
You may also like
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.